Cryptocurrencies: Cryptocurrency quotes are updated in real-time. ValuEngine cut shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a buy rating to a hold rating in a report published on Thursday morning, ValuEngine reports.. GWPH has been the topic of several other reports. Copyright © FactSet Research Systems Inc. All rights reserved. Currently, 15 analysts cover GWPH stock. statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, Source: FactSet. This development strategy, together with the long-term exclusivity potential of Nabiximols, provides G.W. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. GW Pharma stock analysis based on the TipRanks smart score of 8 unique data sets and technical analysis. GWPH management plans to submit the drug to the U.S. Food and Drug Administration FDA, though the earliest this could occur is 2021. Due to the news, H.C. Wainwright analyst Douglas Tsao recently affirmed his Buy rating on GWPH. The stock was sold at an average price of $9.40, for a total value of $225,600.00. That would be GWPH’s first flat quarter as the company moves closer to profitability. GW Pharmaceuticals PLC- (NASDAQ:GWPH) last posted its earnings results on Thursday, August 6th. That would be GWPH’s first flat quarter as the company moves closer to profitability. If Shares of Wynn Resorts Fall Under This Level, Expect a Breakdown, 4 Tech Stocks DEFYING the NASDAQ’s Weakness. Out of 7 analysts covering the stock, GWPH has a consensus analyst rating of Strong Buy with an average price target of $182.67. Get the latest GW Pharmaceuticals PLC GWPH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. attributed to; however, Mr. Lee Davidson, Head of Quantitative Research for Morningstar, Inc., The business’s revenue was up 68.4% compared to the same quarter last year. Tsao said he expects the company to post earnings per share (EPS) of $0.00 for the third quarter of 2020. The stock was sold at an average price of $10.35, for a total value of $186,300.00. I remain bullish on GWPH as I feel that Epidiolex is an essential drug, and should continue to see sales growth. Copyright © 2020. . here Fundamental company data and analyst estimates provided by FactSet. He also hosts a weekly show on YouTube about marijuana stocks. Squarepoint Ops LLC lifted its holdings in shares of GW Pharmaceuticals PLC- by 28.5% during the first quarter. Pharmaceuticals (. ) Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. Source: FactSet, Indexes: Index quotes may be real-time or delayed as per exchange requirements; refer to time stamps for information on any delays. Barron's also provides information on historical stock ratings, … Dynamic Technology Lab Private Ltd lifted its holdings in shares of GW Pharmaceuticals PLC- by 25.6% during the first quarter. Copyright 2020© FactSet Research Systems Inc. All rights reserved. Data are provided 'as is' for informational purposes only and are not intended for trading purposes. Based on analysts offering 12 month price targets for GWPH in the last 3 months. fair value, and uncertainty rating. Don't have a Benzinga account? Sign up to receive Benzinga's Daily Ratings Newsletter, Benzinga's Top Upgrades, Downgrades For August 25, 2020, Cannabis Short Sellers Earn Another $402M In Profits So Far In 2020, 10 Biggest Price Target Changes For Thursday, Cannabis Stock Rally Puts Short Sellers In The Red For 2020, 10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades, Benzinga's Top Upgrades, Downgrades For March 6, 2020, GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020, Privacy Policy / Do Not Sell My Personal Data.